BRAF/NRAS Wild-Type Melanomas Have a High Mutation Load Correlating with Histologic and Molecular Signatures of UV Damage

Purpose: The mutation load in melanoma is generally high compared with other tumor types due to extensive UV damage. Translation of exome sequencing data into clinically relevant information is therefore challenging. This study sought to characterize mutations identified in primary cutaneous melanomas and correlate these with clinicopathologic features. Experimental Design: DNA was extracted from 34 fresh-frozen primary cutaneous melanomas and matched peripheral blood. Tumor histopathology was reviewed by two dermatopathologists. Exome sequencing was conducted and mutation rates were correlated with age, sex, tumor site, and histopathologic variables. Differences in mutations between categories of solar elastosis, pigmentation, and BRAF/NRAS mutational status were investigated. Results: The average mutation rate was 12 per megabase, similar to published results in metastases. The average mutation rate in severely sun damaged (SSD) skin was 21 per Mb compared with 3.8 per Mb in non-SSD skin (P = 0.001). BRAF/NRAS wild-type (WT) tumors had a higher average mutation rate compared with BRAF/NRAS–mutant tumors (27 vs. 5.6 mutations per Mb; P = 0.0001). Tandem CC>TT/GG>AA mutations comprised 70% of all dinucleotide substitutions and were more common in tumors arising in SSD skin (P = 0.0008) and in BRAF/NRAS WT tumors (P = 0.0007). Targetable and potentially targetable mutations in WT tumors, including NF1, KIT, and NOTCH1, were spread over various signaling pathways. Conclusion: Melanomas arising in SSD skin have higher mutation loads and contain a spectrum of molecular subtypes compared with BRAF- and NRAS-mutant tumors indicating multigene screening approaches and combination therapies may be required for management of these patients. Clin Cancer Res; 19(17); 4589–98. ©2013 AACR.

[1]  R. Scolyer,et al.  Biospecimen banking: The pathway to personalized medicine for patients with cancer , 2013, Journal of surgical oncology.

[2]  D. English,et al.  Nodular melanoma: a distinct clinical entity and the largest contributor to melanoma deaths in Victoria, Australia. , 2013, Journal of the American Academy of Dermatology.

[3]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[4]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[5]  R. Scolyer,et al.  Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Matthew J. Davis,et al.  Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma , 2012, Nature Genetics.

[7]  A. Dobrovic,et al.  Detection of BRAF mutations in patients with hairy cell leukemia and related lymphoproliferative disorders , 2012, Haematologica.

[8]  Lauren E Haydu,et al.  Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma , 2012, Clinical Cancer Research.

[9]  Xianqun Fan,et al.  Therapeutic Efficacy by Targeting Correction of Notch1-Induced Aberrants in Uveal Tumors , 2012, PloS one.

[10]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[11]  T. Fennell,et al.  Melanoma genome sequencing reveals frequent PREX2 mutations , 2012, Nature.

[12]  F. Kelleher,et al.  Targeting NRAS in Melanoma , 2012, Cancer journal.

[13]  K. Dutton-Regester,et al.  A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma , 2012, Molecular Cancer Therapeutics.

[14]  T. Hudson,et al.  The Genetic Basis for Cancer Treatment Decisions , 2012, Cell.

[15]  A. Ashworth,et al.  Whole genome sequencing of matched primary and metastatic acral melanomas. , 2012, Genome research.

[16]  J. Handa,et al.  Notch Signaling Promotes Growth and Invasion in Uveal Melanoma , 2012, Clinical Cancer Research.

[17]  C. V. Jongeneel,et al.  Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma , 2011, Nature Genetics.

[18]  R. Gibbs,et al.  Frequent somatic MAP3K5 and MAP3K9 mutations in metastatic melanoma identified by exome sequencing , 2011, Nature Genetics.

[19]  Lee T. Sam,et al.  Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.

[20]  Gautier Koscielny,et al.  Ensembl 2012 , 2011, Nucleic Acids Res..

[21]  David C Whiteman,et al.  The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin , 2011, Pigment cell & melanoma research.

[22]  C. Tzen,et al.  Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma , 2011, Pigment cell & melanoma research.

[23]  S. Davis,et al.  Exome sequencing identifies GRIN2A as frequently mutated in melanoma , 2011, Nature Genetics.

[24]  J. Tenenbaum,et al.  A Melanoma Molecular Disease Model , 2011, PloS one.

[25]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[26]  D. Schadendorf,et al.  Genetic and morphologic features for melanoma classification , 2010, Pigment cell & melanoma research.

[27]  Li-E. Wang,et al.  Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma , 2010, Clinical Cancer Research.

[28]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[29]  Jimmy Lin,et al.  Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4 , 2009, Nature Genetics.

[30]  Chenwei Wang,et al.  Analysis of the matrix metalloproteinase family reveals that MMP8 is often mutated in melanoma , 2009, Nature Genetics.

[31]  Susan Muller,et al.  KIT Gene Mutations and Copy Number in Melanoma Subtypes , 2008, Clinical Cancer Research.

[32]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[33]  G. Saldanha,et al.  Cutaneous Melanoma Subtypes Show Different BRAF and NRAS Mutation Frequencies , 2006, Clinical Cancer Research.

[34]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[35]  M. Trivett,et al.  Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. , 2007, The Journal of investigative dermatology.

[36]  Ajay N. Jain,et al.  Determinants of BRAF mutations in primary melanomas. , 2003, Journal of the National Cancer Institute.

[37]  A. Scarpa,et al.  Pathology and Genetics , 2010 .

[38]  F. Collins,et al.  Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients , 1992, Nature.

[39]  杨凌春,et al.  Broad Institute , 2014 .

[40]  K. Flaherty,et al.  Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. , 2012, European journal of cancer.

[41]  M. Weinstock,et al.  The contribution of nodular subtype to melanoma mortality in the United States, 1978 to 2007. , 2012, Archives of dermatology.

[42]  Gurpreet W. Tang,et al.  COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer , 2010, Nucleic Acids Res..

[43]  Jane Fridlyand,et al.  Improving Melanoma Classification by Integrating Genetic and Morphologic Features , 2008, PLoS medicine.

[44]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.